-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2437 Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis

Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Hematology Disease Topics & Pathways:
Biological, Diseases, bone marrow, Non-Biological, Therapies, MPN, Myeloid Malignancies, transplantation
Sunday, December 6, 2020, 7:00 AM-3:30 PM

Donal P. McLornan, MRCP, PhD, FRCPath1*, Dirk-Jan Eikema2*, Nicolaus Kröger, MD3*, Linda Koster4*, Tomasz Czerw, MD, PhD5*, Dietrich W. Beelen, MD6, Emanuele Angelucci7*, Marie Robin, MD, PhD8, Martin Bornhaeuser, MD9, Jakob Passweg10*, Grant McQuaker, MD11, Antonin Vitek12*, Jürgen Finke Sr., MD, PhD13, Igor W Blau, MD, PhD14*, Riitta Niittyvuopio15*, Uwe Platzbecker, MD16, Jan J. Cornelissen, MD, PhD17, Patrice Chevallier, MD, PhD18, Micha Srour19*, Dragana Stamatovic, MD, PhD20*, Joaquín Martínez-Lopez21*, Liesbeth C. de Wreede, PhD22*, Patrick J Hayden, MD23, Juan Carlos Hernandez Boluda24* and Ibrahim Yakoub-Agha25

1Department of Clinical Haematology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
2Department of Statistics, Leiden University Medical Centre, Leiden, Netherlands
3Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
4EBMT Data Office Leiden, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands
5Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
6Department of Bone Marrow Transplantation, University of Essen, Essen, Germany
7Hematology and Transplant Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
8Hôpital Saint-Louis, APHP, Paris, France
9Universitatsklinikum Cad GustavCarus an der Technischen Universltat Dresden, Dresden, Ferscherstrabo 74, Germany
10Hematology, University Hospital Basel, Basel, Switzerland
11Beatson West of Scotland Cancer Centre, Glasgow, GBR
12Hematology Service, Institute of Hematology and Blood Transfusion, Prague, Czech Republic, PRAGUE, Czech Republic
13University of Freiburg, Freiburg, Germany, Dept. of Hematology, Oncology and Stem Cell Transplantation,, Freiburg, Germany
14Charité Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, Berlin, Germany
15Helsinki Hospital, HELSINKI, FIN
16Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
17Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
18Hematology Clinic, CHU Nantes, Nantes, France
19Hôpital Huriez, CHU de Lille, Lille, France
20Military Medical Academy, Belgrade, SRB
21Department of Hematology, Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid, Spain
22LUMC, Dept. Medical Statistics & Bioinformatics, Leiden, Netherlands
23Department of Haematology, St. James's Hospital, Dublin, Ireland
24Hospital Clínico Universitario, VALENCIA, Spain
25Univ Lille, CHU de Lille, INFINITE, INSERM U1286, 59000 Lille, LILLE, France

Aim: Dynamic assessment of trends over time in patient- and transplant-specific characteristics and outcomes for patients undergoing 1st allogeneic haematopoietic cell transplant (allo-HCT) for Myelofibrosis (MF).

Methods and Results: A total of 4142 MF patients were analysed who underwent allo-HCT between 1995-2018 (24-year period) across 278 centres based on data reported to the European Society for Blood and Marrow Transplantation. For analysis, 4 cohorts were considered based on year of allo-HCT: <2006 n=389 (9.4%), 2006-2010 n=910 (22%), 2011-2014 n=1148 (27.7%) and 2015-2018 n=1695 (40.9%). A steady increase in MF allo-HCT activity over time was apparent paralleled with increasing numbers of participating transplant centres. A total of 2603 (62.8%) patients were male, 3239 (78.2%) had Primary MF, 409 (9.9%) and 494 (11.9%) post-Polycythaemia Vera and post-Essential Thrombocythaemia MF, respectively. An increased median interval (lnterquartile range (IQR)) between diagnosis and transplant was evident over time (<2006 median 20.8 (8.9-62.2) months versus 36.2 (11.6-107.5) months in 2015-2018 period;p<0.001), potentially reflecting increased availability of therapeutics in recent eras (untreated patients <2006= 59.4% versus 2015-2018=23.7%). Median recipient age (IQR) increased over time by ~ a decade between earliest cohort and most recent: <2006, 49.4 years (43.1-55.3) versus 59.3 years (53.4-64.8)2015-2018. Prior to 2006, patients >60 years accounted for 8.7% of adults undergoing allo-HCT whereas for 2015-2018 this was 47%. Over time, increasing number of patients with a Karnofsky performance status (KPS) <90 underwent allo-HCT (<2006=19.7% versus 36.1% 2015-18; p<0.001). Peripheral Blood (PB) was the predominant stem cell source and utilisation increased over time, accounting for 74.8% <2006 and 92.2% within 2015-2018 cohort. Cord blood utilisation was limited to <1% throughout the 24-year study period. Significant shifts towards use of unrelated donors (URD) in more recent periods was apparent (p<0.001). Moreover, increased use of mismatched related donors (MMRD) was particularly evident in 2015-2018 cohort; n=152 (9%) versus n=74 (3%) cumulative for other 3 cohorts combined; p<0.001. Decreased use of myeloablative and TBI- based conditioning was evident over time (p<0.001). Specifically, there was increased use of busulphan-based regimens (<2006: 44.2% versus 2015-2018: 72%). Regarding T cell depletion, trends demonstrated increased use of anti-thymocyte globulin (ATG) over time (<2006=37.3% vs 69.9% 2015-2018; p<0.001). Median time to both neutrophil (median 18 days across all cohorts) and platelet engraftment was similar in all 4 cohorts, with no significant variation when stratified by period of transplantation. Allo-HCT outcomes, survival, GVHD and relapse endpoints are shown for all 4 cohorts in Table 1. Overall for the entire group, significant factors associated with worse OS, RFS and NRM remained older age and a poor KPS (<90). No significant differences between cohorts were noted for either estimated 3-year OS (<2006=55% (50-60%), 2006-2010=60% (56-63%), 2011-2014 and 2015-2018= 58% (55-61%); p=0.299) or non-relapse mortality (NRM (Table 1); p=0.523), despite increasing numbers of older, less fit patients, and more frequent HLA-mismatched transplants over time. To investigate survival findings in more detail an adjusted model will be presented including period of allo-HCT and transplant-related variables. Cumulative incidence of relapse at 3 years was similar across all cohorts, suggesting no significant changes with time. Most common causes of death across all 4 cohorts remained GVHD and infection. Of note, rates of acute (a)GVHD grade II-IV by day +100 decreased from the earliest cohort <2006 compared to the later groups (p=0.027) as did rates of overall chronic (c) GVHD whereby this was evident in 57% (95% CI 52-62%) <2006 cohort compared to 44% (95% CI 42-47%) in the 2015-2018 group, predominantly reflected by reductions in extensive cGVHD (Table 1).

Conclusions: Despite a marked increase over this 24-year period in recipient age, RIC regimen utilisation and use of both URD and MMRD, this comprehensive analysis demonstrates stable OS and EFS rates. However, rates of GVHD have decreased over time, in particular extensive cGVHD. Further work is required to improve both the considerable NRM and relapse rates which remain significant.

Disclosures: McLornan: JAZZ PHARMA: Honoraria, Speakers Bureau; CELGENE: Honoraria, Speakers Bureau; NOVARTIS: Honoraria, Speakers Bureau. Platzbecker: JAZZ: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Bergenbio: Research Funding; Janssen: Honoraria, Research Funding; BMS: Honoraria, Research Funding. Chevallier: Incyte Corporation: Honoraria. Martínez-Lopez: Altum, Hosea: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Vivia Biotech: Honoraria; Amgen: Speakers Bureau; Takeda: Speakers Bureau; Roche: Speakers Bureau; Janssen: Speakers Bureau; Incyte: Research Funding, Speakers Bureau; Bristol Myers Squibb: Research Funding, Speakers Bureau; Novartis: Research Funding. Yakoub-Agha: Celgene: Honoraria; Jazz Pharmaceuticals: Honoraria; Novartis: Honoraria; Gilead/Kite: Honoraria, Other: travel support; Janssen: Honoraria.

*signifies non-member of ASH